Thursday, 1 October 2009
US STUDY RESULTS
OBJ Limited (ASX: OBJ) advises that it has now received the final report from Azopharma
covering the Company’s research collaboration with a global Fast Moving Consumer Goods
(FMCG) company. The report by Azopharma Contract Services Inc, a GLP/GMP accredited
contract research organisation in Miami Florida, sets out the results of an eight-month patch
development and evaluation program. The study tested the delivery performance of OBJ’s
Dermaportation and ETP technologies in a fully formulated patch format, when compared to
an existing Over the Counter (OTC) drug product with significant international sales.
In 2008, OBJ advised the market that it had entered into an Agreement with a major
international FMCG company to evaluate OBJ’s two main technologies and had engaged
Azopharma Contract Services Inc as the independent Contract Research Organisation (CRO) to
undertake the formulation and evaluation phases.
The FMCG company’s stated objective in the Agreement with OBJ was to achieve up to a 10-
fold increase in drug delivery over an existing commercial product. Under the terms of the
Agreement, OBJ is restricted from disclosing any information relating to the drug tested, the
comparative product or the market. However the following graph by Azopharma illustrates
the relative performance and the achievement of the FMCG’s objectives.
Sorry but couldnt paste, but suffice to say the graph tells a big story...
The Azopharma Report, which remains the property of the FMCG company, stated in
the Executive Summary that:
“The developed patch system effectively fluxes
approximately a 10-fold over the existing product
comparatively”
“The development work to this point justifies proof-ofconcept
of the formulation and technology to proceed
further into the pharmaceutical development of a drug
product.”
OBJ is very pleased to have independent validation by an internationally accredited
laboratory. It provides confidence and lays the foundations for potential commercial
development in pharmaceutical and cosmetic applications.
These test results are significant to the Company to the extent that attention to
development of selected patch products with suitable international partners can now
become more focused. It is the intention of OBJ to expedite securing commercial
partners to embrace the use of OBJ’s patch technologies into the most appropriate
applications.
- Forums
- ASX - By Stock
- WFL
- forget trader noise and look at the big scene
forget trader noise and look at the big scene
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add WFL (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.478M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
WFL (ASX) Chart |
Day chart unavailable